54738-73-7

Basic information

• Product Name: 3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL
• Synonyms: 3-bromo-1H-indazol-4-ol;3-broMo-1H,4H,5H-pyrazolo[3,4-d]pyriMidin-4-one;3-BroMo-1H-pyrazolo[3,4-d]pyriMidin-4(5H)-one;3-Bromo-4-hydroxypyrazolo[3,4-d]pyrimidine;3-Bromoallopurinol;NSC 344532;3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL;3-Bromo-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
• CAS NO: 54738-73-7
• Molecular Formula: C₅H₃BrN₄O
• Molecular Weight: 215.01
• EINECS: 205-525-8
• Mol File: 54738-73-7.mol

Chemical Properties

• Melting Point: 350℃
• Boiling Point: 473.096 °C at 760 mmHg
• Flash Point: 239.92 °C
• Appearance: /
• Density: 2.236 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.834
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.16±0.70(Predicted)
• CAS DataBase Reference: 3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL(54738-73-7)
• EPA Substance Registry System: 3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL(54738-73-7)

Safety Data

• Hazardous Substances Data: 54738-73-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL is used as a research compound for its unique structure and reactivity, contributing to the understanding of pyrazolopyrimidines and their potential applications in chemistry.
Used in Biochemical Studies:
3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL is used as a biochemical research tool to explore its interactions with biological systems, potentially leading to insights into its role in biological processes and the development of new therapeutic strategies.

InChI:InChI=1/C5H3BrN4O/c6-3-2-4(10-9-3)7-1-8-5(2)11/h1H,(H2,7,8,9,10,11)

Upstream product

• 315-30-0 4-hydroxypyrazolo(3,4-d)pyrimidine 
• 5399-92-8 4-chloro-1H-pyrazolo[3,4-d]pyrimidine 
• 315-30-0 Allopurinol 

Downstream Products

• 90914-30-0 3-bromo-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-pyrazolo<3,4-d>pyrimidin-4(5H)-one 
• 14246-71-0 3-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 

Relevant articles and documents

Revisiting Pyrazolo[3,4- d]pyrimidine Nucleosides as Anti- Trypanosoma cruzi and Antileishmanial Agents

Chagas disease and visceral leishmaniasis are two neglected tropical diseases responsible for numerous deaths around the world. For both, current treatments are largely inadequate, resulting in a continued need for new drug discovery. As both kinetoplastid parasites are incapable of de novo purine synthesis, they depend on purine salvage pathways that allow them to acquire and process purines from the host to meet their demands. Purine nucleoside analogues therefore constitute a logical source of potential antiparasitic agents. Earlier optimization efforts of the natural product tubercidin (7-deazaadenosine) involving modifications to the nucleobase 7-position and the ribofuranose 3′-position led to analogues with potent anti-Trypanosoma brucei and anti-Trypanosoma cruzi activities. In this work, we report the design and synthesis of pyrazolo[3,4-d]pyrimidine nucleosides with 3′- and 7-modifications and assess their potential as anti-Trypanosoma cruzi and antileishmanial agents. One compound was selected for in vivo evaluation in an acute Chagas disease mouse model.

TRIAZOLONE COMPOUNDS AS PERK INHIBITORS

The invention is directed to substituted triazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, X, Y, Y1, and Z are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Pyrazolopyrimidines as therapeutic agents

The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

Pyrazolopyrimidines as therapeutic agents

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R2, and R3 are defined as described herein.